Introducing SPEAR epTau 217 and eMTBR-Tau: Dissecting Alzheimer’s pathologies from early Tau phosphorylation to Tau tangles
Wednesday, September 9 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
This webinar will introduce two novel blood-based biomarker assays for Alzheimer's disease (AD): SPEAR epTau 217 and SPEAR eMTBR-Tau.
SPEAR epTau 217 detects a unique subset of pTau 217 that may represent an early and distinct AD-associated Tau species. We will present data demonstrating that SPEAR epTau 217 provides highly consistent measurements between paired venous and Tasso capillary blood samples, outperforming other Tau biomarkers, including total pTau 217, BD-Tau, and BD-pTau 217.
SPEAR eMTBR-Tau measures a plasma biomarker associated with neurofibrillary tangle pathology in late-stage AD. We will share data showing that plasma eMTBR-Tau increases markedly with advanced disease, correlating with neuropathological severity and Tau-PET burden, highlighting its potential as a blood-based marker of Tau tangle pathology.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speakers
Who should attend?
Academic researchers, pharmaceutical and biotechnology teams, CROs, translational scientists, and clinical laboratory researchers interested in Alzheimer’s disease biomarkers, tau biology, biomarker validation, clinical research, and the research-use evaluation of eMTBR-Tau and pTau 217.
What will this webinar cover?
- The biological rationale for targeting early phosphorylation at Tau 217 (epTau 217) and microtubule-binding region Tau (eMTBR-Tau) as complementary blood-based biomarkers of Alzheimer's disease.
- How SPEAR epTau 217 and SPEAR eMTBR-Tau provide complementary insights into different stages of AD pathology, from early Tau alterations to neurofibrillary tangle formation.
- Analytical and clinical performance data demonstrating the robustness of SPEAR epTau 217 across venous and capillary blood collection, and the association of SPEAR eMTBR-Tau with Tau-PET burden and neuropathological severity.
- Potential applications of these next-generation biomarkers in AD research, clinical studies, and decentralized sample collection workflows.